Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 1.00 |
| ▸ | CNR1 | P21554 | 10/20 | 1.00 |
| ▸ | LDHA | P00338 | 2/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 1.00 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | ABHD12 | Q8N2K0 | 3/20 | 0.64 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.64 |
| ▸ | FAAH | O00519 | 2/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.64 |
| ▸ | GPR183 | P32249 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.64 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.64 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.64 |
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delta9-Tetrahydrocannabinolic Acid A SCHEMBL6856735 | 1.00 | CNR2 (1.00) | CNR2CNR1LDHATRPM8DAGLA | |
| Delta9-Tetrahydrocannabinolic Acid A SCHEMBL18095976 | 1.00 | CNR2 (1.00) | CNR2CNR1LDHATRPM8DAGLA | |
| Delta9-Tetrahydrocannabinolic Acid A SCHEMBL14773902 | 1.00 | CNR2 (1.00) | CNR2CNR1LDHATRPM8DAGLA | |
| Delta9-Tetrahydrocannabinolic Acid A SCHEMBL29691633 | 1.00 | CNR2 (1.00) | CNR2CNR1LDHATRPM8DAGLA | |
| Delta9-Tetrahydrocannabinolic Acid A SCHEMBL29610699 | 1.00 | CNR2 (1.00) | CNR2CNR1LDHATRPM8DAGLA | |
| Delta9-Tetrahydrocannabinolic Acid A SCHEMBL23076463 | 1.00 | CNR2 (1.00) | CNR2CNR1LDHATRPM8DAGLA | |
| SCHEMBL25215172 | 0.99 | CNR2 (0.98) | CNR2CNR1LDHATRPM8DAGLA | |
| SCHEMBL23121713 | 0.99 | CNR2 (0.98) | CNR2CNR1LDHATRPM8DAGLA | |
| SCHEMBL22691773 | 0.99 | CNR2 (0.98) | CNR2CNR1LDHATRPM8DAGLA | |
| SCHEMBL23874170 | 0.99 | CNR2 (0.98) | CNR2CNR1LDHATRPM8DAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029718-B2 | Process for production of essentially pure delta-9-tetrahydrocannabinol | CCT SCIENCES, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-11684598-B2 | Use of cannabinoids in the treatment of epilepsy | GW Research Limited (GB) | 2023-06-27 | — | — | US | disclosed |
| US-20230149342-A1 | Process for production of essentially pure delta-9-tetrahydrocannabinol | CCT SCIENCES, LLC | 2023-05-18 | — | — | US | disclosed |
| US-11596618-B2 | Oral cannabinoid delivery formulations with mouthfeel experience enhancers | Resurgent Biosciences, Inc. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220387352-A1 | CANNABINOID COMPOSITIONS AND METHODS OF USING FOR THE TREATMENT OF NON-EOSINOPHILIC INFLAMMATION AND INFLAMMATORY DISORDERS | MEDTERRA PHARMA LLC | 2022-12-08 | — | — | US | disclosed |
| US-20220280582-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2022-09-08 | — | — | US | disclosed |
| US-20220213428-A1 | APPARATUS, METHODS AND COMPOSITION FOR SYNTHESIS OF CANNABINOID COMPOUNDS | TEEWINOT LIFE SCIENCES CORPORATION (US) | 2022-07-07 | — | — | US | disclosed |
| US-11344591-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2022-05-31 | — | — | US | disclosed |
| US-20220154197-A1 | CANNABINOID PRECURSOR PRODUCTION | PERPETUUM CROPSCIENCE BVBA (BE) | 2022-05-19 | — | — | US | disclosed |
| US-11331358-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2022-05-17 | — | — | US | disclosed |
| US-20160074451-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2016-03-17 | — | — | US | disclosed |
| US-20160074451-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2016-03-17 | — | — | US | disclosed |
| US-9186386-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-11-17 | — | — | US | disclosed |
| US-9186386-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-11-17 | — | — | US | disclosed |
| US-20150297653-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | disclosed |
| US-20150297653-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | disclosed |
| US-20150297654-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | disclosed |
| US-20150297654-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | disclosed |
| US-9044390-B1 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-06-02 | — | — | US | disclosed |
| US-9044390-B1 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387352-A1 | CANNABINOID COMPOSITIONS AND METHODS OF USING FOR THE TREATMENT OF NON-EOSINOPHILIC INFLAMMATION AND INFLAMMATORY DISORDERS | CNR2, CNR1, FAAH2 | CNR2 1/4885CNR1 2/4885LDHA 4724/4885 |
| US-11344591-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | CNR2 1/4885CNR1 2/4885LDHA 4853/4885 |
| US-11331358-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | CNR2 1/4885CNR1 2/4885LDHA 4853/4885 |
| US-20160074451-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | CNR2 1/4885CNR1 2/4885LDHA 4853/4885 |
| US-20150297654-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | CNR2 1/4885CNR1 2/4885LDHA 4853/4885 |
| US-11596618-B2 | Oral cannabinoid delivery formulations with mouthfeel experience enhancers | CNR2, CNR1, CPNE4 | CNR2 1/4885CNR1 2/4885LDHA 4444/4885 |
| US-20220280582-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | CNR2 1/4885CNR1 2/4885LDHA 4853/4885 |
| US-20230149342-A1 | Process for production of essentially pure delta-9-tetrahydrocannabinol | CNR2, CNR1, DAGLA | CNR2 1/4885CNR1 2/4885LDHA 1294/4885 |
| US-20150297653-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | CNR2 1/4885CNR1 2/4885LDHA 4853/4885 |
| US-11684598-B2 | Use of cannabinoids in the treatment of epilepsy | CNR2, CNR1, GABRQ | CNR2 1/4885CNR1 2/4885LDHA 2887/4885 |
| US-12029718-B2 | Process for production of essentially pure delta-9-tetrahydrocannabinol | CNR2, CNR1, DAGLA | CNR2 1/4885CNR1 2/4885LDHA 1294/4885 |
| US-20220154197-A1 | CANNABINOID PRECURSOR PRODUCTION | DHX29, DHX9, PHAX | CNR2 30/4885CNR1 24/4885LDHA 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.